Company Overview - Attovia Therapeutics has appointed Steven Chan as Chief Financial Officer, bringing over thirty years of financial leadership experience across various sectors including biotechnology and healthcare [1][2] - The company focuses on developing a pipeline of biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY™ platform [3] Leadership and Strategy - Steven Chan's previous experience includes serving as CFO at Connect Biopharma and Delphon Industries, as well as holding financial leadership roles at several publicly traded companies [2] - CEO Tao Fu emphasized that Chan's track record in private-to-public transitions and public-stage companies is crucial for Attovia's expansion and corporate strategy [2] Technology and Innovation - Attovia's ATTOBODY™ platform enables the creation of bispecific and multispecific therapeutics with high potency and tunable half-lives, potentially allowing for less frequent dosing [3] - The platform utilizes spatial positioning technology for biparatopic target engagement, achieving picomolar affinity and glue-like off-rates, which enhances the biologic activity of the therapeutics [3]
Attovia Therapeutics Appoints Chief Financial Officer